Request Trial
shutterstock_1028628301_yasonya
Yasonya / Shutterstock.com
27 January 2020Pharma

Conference preview: 12th Pharma & Biotech Patent Litigation

The event comes at a significant time for European IP, with political uncertainty and the current state of IP proving a series of challenges for pharmaceutical and biotech companies conducting business in Europe.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Accord’s generic hopes dashed in cyanide antidote ruling
14 October 2026   Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.
Pharma
Novo’s semaglutide protection weakens after European ruling
13 October 2026   Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.
Pharma
Novartis pursues Apotex over copies of $2bn skin cancer drug franchise
8 October 2026   Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen.


Editor's picks

Boston Scientific expands dispute with J&J unit over cardiac-access technology
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026

Editor's picks

MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026
Pharma
Behind the case: How Novartis defended its blockbuster Entresto in the UK
22 September 2026
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

More features

Haynes Boone expands in California with new office
Accord’s generic hopes dashed in cyanide antidote ruling
Novo’s semaglutide protection weakens after European ruling
Brazilian firm appoints patent strategist to lead department
Novartis pursues Apotex over copies of $2bn skin cancer drug franchise
MSD’s Keytruda hit by eight-country ban across Europe
WATCH: LEO Pharma head of IP rights on doing more with less
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom